Income statement
USD
Annual
| Metric | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|
| Revenue | 26M | 23M | 11M | 8K | 99K |
| Gross Profit | 9M | 7M | 2M | -37K | 80K |
| Operating Income | -2M | -10M | -4M | -2M | -786K |
| EBITDA | -2M | -10M | -2M | -2M | -756K |
| Net Income | -4M | -21M | -9M | -3M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Synovics Pharmaceuticals, Inc. (SYVC) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +10.6%, EPS growth of +84.4%, a dividend yield of 0.0%. What stands out right now is revenue +10.6%, EPS +84.4%, free cash flow +171.8% with operating margin -9.6% and ROIC -21.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines SYVC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYVC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYVC Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYVC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$98.8K
+1105.7% YoY
FY Net Income
-$1.1M
+61.4% YoY
Free Cash Flow
-$653.9K
+73.8% YoY
Revenue Growth
+10.6%
EPS Growth
+84.4%
Gross Margin
34.6%
Net Margin
-15.4%
Income statement
USD
| Metric | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|
| Revenue | 26M | 23M | 11M | 8K | 99K |
| Gross Profit | 9M | 7M | 2M | -37K | 80K |
| Operating Income | -2M | -10M | -4M | -2M | -786K |
| EBITDA | -2M | -10M | -2M | -2M | -756K |
| Net Income | -4M | -21M | -9M | -3M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|
| Cash & Equivalents | 66K | 0 | 2M | 129K | 629K |
| Total Assets | 22M | 23M | 39M | 17M | 3M |
| Total Liabilities | 17M | 31M | 26M | 6M | 2M |
| Shareholder Equity | 5M | -8M | 13M | 11M | 905K |
| Total Debt | 7M | 19M | 18M | 4M | 0 |
| Net Debt | 6M | 19M | 15M | 4M | -629K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
640K
+71.6% YoY
Capital Expenditures
13K
+94.3% YoY
Free Cash Flow
654K
+73.8% YoY
Key ratios
Gross Margin
34.6%
Operating Margin
-9.6%
Net Margin
-15.4%
ROE
258.2%
Debt / Equity
1.31x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.